ESMO Clinical Guidelines Sessions

Introduction

Sunday 21 October 2018
ESMO 2018, Munich

George Pentheroudakis
George Pentheroudakis

Honoraria received for speaker, advisory role, research funding:
- Amgen, Merck, Astra Zeneca, Roche, Novartis, BMS, MSD, Lilly, Boehringer, Roche
ESMO Clinical Practice Guidelines

Delivering evidence-based high quality practice recommendations to the oncology professional
ESMO Clinical Practice Guidelines

- Evidence-based guidelines, 20-40 pages long
- The standard for best practice
- Available on the ESMO and OncologyPRO websites
- Published in Annals of Oncology

ESMO Consensus Guidelines

- Guidelines derived from Consensus Conferences (1 or 2 day meeting)
- Pre-selected controversial questions addressed by multidisciplinary experts on specific tumour types
ESMO Clinical Practice Guidelines

5 new titles:
Management of anaemia and iron deficiency in patients with cancer
Diagnosis, assessment and management of constipation in advanced cancer
Diarrhoea in adult cancer patients
Delirium in adult cancer patients
Hepatocellular carcinoma

9 updated Guidelines:
Non-epithelial ovarian cancer
Hodgkin lymphoma
Primary cutaneous lymphomas
Waldenström’s macroglobulinaemia
Soft tissue and visceral sarcomas
Gastrointestinal stromal tumours
Bone sarcomas
Management of cancer pain in adult patients
Metastatic non-small cell lung cancer
An electronic update (eUpdate) will be produced:

- when a breakthrough has occurred necessitating rapid “emergency” communication
- when a MCBS score has been produced for a new EMA-approved therapy
ESMO Pocket Guidelines

- Easily accessible abridged versions of ESMO Clinical Practice Guidelines
- Available online from esmo.org
- Printed copies at the ESMO booth and exhibition hall
ESMO-standardised algorithm

Algorithm on therapeutic strategy or management according to stage, risk factors and disease/molecular characteristics.
• Set of 15-20 slides for each CPG title to be developed
• Free to download from esmo.org
• Concise: algorithms and tables with key recommendations
Published:

- Early and locally advanced non-small cell lung cancer
- Toxicities from immunotherapy

Planned next:

- Rectal cancer
- Non-epithelial ovarian cancer
- Hodgkin lymphoma
- Soft tissue and visceral sarcoma
- Cancer pain
- Metastatic non-small lung cancer
- Early breast cancer
- Metastatic colorectal cancer
- GEP-NETs
ESMO Guidelines pages

In 2016 and 2017 there were over 1 million unique page views* of ESMO Guidelines pages on the ESMO.org website.

These totals represent approximately 22% of all unique page views on the ESMO.org website.

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>89,530</td>
</tr>
<tr>
<td>2012</td>
<td>100,738</td>
</tr>
<tr>
<td>2013</td>
<td>394,889</td>
</tr>
<tr>
<td>2014</td>
<td>734,150</td>
</tr>
<tr>
<td>2015</td>
<td>892,540</td>
</tr>
<tr>
<td>2016</td>
<td>1,052,185</td>
</tr>
<tr>
<td>2017</td>
<td>1,377,993</td>
</tr>
</tbody>
</table>

*Unique page views: the number of visits during which the a page was viewed one or more times.
Don’t forget to pick up your copies

Clinical Practice Guidelines

Pocket Guidelines

Patient Guides
Session 1: 10h45-12h45
- GEP NETs (Julien Hadoux, Alfredo Berruti)
- Mantle cell lymphoma (Mats Jerkeman, Martin Dreyling)
- Rectal cancer (Francesco Sclafani, Andrés Cervantes)
- Metastatic NSCLC: resistance to EGFR TKIs (Martin Früh, Pasi Jänne)

Session 2: 14h30-16h30
- Early HER2-positive breast cancer (Simona Volovat, Elżbieta Senkus-Konefka)
- Soft tissue sarcoma (Bruna David, Silvia Stacchiotti)
- Cancer cachexia (Tora Skeidsvoll-Solheim, Jann Arends)
- Prostate cancer (Maria Serra, Chris Parker)